Formulation regularity and optimal compatibility ratio of "Huangqi-Baizhu" drug pairs for treating liver cancer
OBJECTIVE To explore the composition regularity and optimal compatibility ratio of traditional Chinese medi-cine(TCM)formulas containing Huangqi-Baizhu(HB)for treating liver cancer(LC)and provide rationales for rational clinical application of HB for LC.METHODS The databases of China National Knowledge Infrastructure(CNKI),Wanfang and VIP were employed as prescription sources for selecting suitable prescriptions and extracting drug information.Excel 2019,SPSS Modeler 18.0,SPSS Statistics 24.0,TCM Inheritance Auxiliary Platform V2.50 and RevMan5.3 statistical software were employed for grouping analysis and clinical efficacy evaluations.Optimal ratio of Huangqi-Baizhu for treating LC was assessed by cell proliferation and murine survival assays.RESULTS Composition analysis showed that Top 5 traditional Chinese medicines in terms of compatibility frequency with HB were Poria cocos,licorice,Coix seed,malt and Bupleurum chinense.The most com-mon types of medications were of tonifying deficiency followed by those of clearing heat,promoting blood circulation and resolving blood stasis and promoting water and dampness.Meta-analysis demonstrated not much bias among all included articles.Treat-ment group of HB achieved a significantly higher effective rate in short-term treatment than control group[OR=2.31,95％CI(1.80,2.97),P＜0.0001].LC cell proliferation assay indicated that,at a ratio of Huangqi-Baizhu of 1∶1,2∶1 and 1∶2,the val-ues of half maximal inhibitory concentration(IC50)were 64.71,68.40 and 69.08 mg·mL-1 respectively.And survival assay revealed that the highest survival rate was 62.5％at a ratio of 1∶2.Tumor inhibition rate peaked at 35.97％.CONCLUSION HB pair is widely applied for clinical treatment of LC.HB and its combination accord well with the clinical therapeutic principles of LC and offer excellent therapeutic outcomes.At the same time,at a formulation ratio of 1∶2,survival rate is the highest for LC mice.Thus it provides rationales for clinical rational formulation of HB.
Huangqi-Baizhuformulation regularityMeta-analysiscompatibility ratioprimary liver cancer
NETL
